UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...
Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
Statewide Practice Enrolling Patients in Global, Late-Phase Clinical Trial ...
The growing use of immuno-oncology, advancing bioinformatics analysis, and rising investment in precision medicine are driving the immune repertoire sequencing market.Austin, Texas, Jan. 22, 2026 ...
The D-Domain binder has a fast off-rate and contributes to anito-cel’s differentiated pharmacology profile in multiple myeloma ---- A simulation model of CAR T use ahead of bispecific antibodies in ...
The FDA has granted breakthrough therapy designation (BTD) to soficabtagene geleucel (sofi-cel; WU-CART-007) for the ...
The overall sentiment of these big-money traders is split between 42% bullish and 50%, bearish. Out of all of the options we uncovered, there was 1 put, for a total amount of $27,360, and 13, calls, ...
Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological malignancies, today announced that it has received ...
CAR031's global reach," including in China, as a potential treatment for liver and other solid tumors, AbelZeta CEO Tony Liu said.
Immunocore is expanding its ImmTAX platform into autoimmune disease, outlining plans to start first‑in‑human trials of ...
CAR T cells have made headlines for their ability to fight hematological cancers, but they have proven largely ineffective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results